NICE disappoints Roche again with Gazyvaro no
This article was originally published in Scrip
Executive Summary
NICE has rejected Roche's Rituxan (rituximab) follow-on Gazyvaro (obinutuzumab) after its committee pointed out uncertainties with Roche's submission. It is the latest in a run of NICE cancer drug rejections for Roche, and the company said it was "very disappointed" with the decision.